Giant cell arteritis

References

• Kermani TA, Schafer VS, Crowson CS, et al. Increase in age at onset of giant cell arteritis: a population-based study. Ann Rheum Dis. 2010;69(4):780.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Vazquz-Rodriguez TR, Lopez-Diaz MJ, et al. Epidemiology of giant cell and arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009;61:1455.
   Web of Science ®Google Scholar
• Crowson CS, Matteson EL, Myasoedova E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 2011;63:636.
   Web of Science ®Google Scholar
• Salvarani C, Crowson CS, O’Fallon WM, et al. Reappraisal of the epidemiology of giant cell arteritis in Olmstead County, Minnesota, over a fifty-year period. Arthritis Rheum. 2004;51:264.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Porrua C. Epidemiology of the vasculitides. Rheum Dis Clin North Am. 2011;27:729–749.
   Web of Science ®Google Scholar
• Boesen P, Sorensen SF. Giant cell arteritis, temporal arteritis, and polymyalgia rheumatica in aDanish county: a prospective investigation, 1982-1985. Arthritis Rheum. 1987;30:294–4.
   PubMed Web of Science ®Google Scholar
• Gran JT, Myklebust G. The incidence of polymyalgia rheumatic and temporal arteritis in the country of Aust Agder, south Norway: a prospective study 1987-94. J Rheumatol. 1997;24:173943.
   Web of Science ®Google Scholar
• Petursdottir V, Johansson H, Nordborg E, et al. The epidemiology of biopsy-positive giant cell arteritis: special reference top cyclic fluctuations. Rheumatology (Oxford). 1998;38:1208–1212.
   Web of Science ®Google Scholar
• De Smit E, Palmer AJ, Hewitt AW. Projected worldwide disease burden from giant cell arteritis by 2050. J Rheumatol. 2015;42:119.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Miranda-Filloy JA, Lopez-Diaz MJ, et al. Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study. Medicine (Baltimore). 2007;86:61.
   PubMed Web of Science ®Google Scholar
• Pamuk ON, Donmez S, Karahan B, et al. Giant cell arteritis and polymyalgia rheumatica in northwestern Turkey: clinical feature and epidemiological data. Clin Exp Rheum. 2009;27:830.
   PubMed Web of Science ®Google Scholar
• Salvarini C, Macchioni P, Zizzi F, et al. Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. Arthritis Rheum. 1991;34:351–356.
   PubMed Web of Science ®Google Scholar
• Smith CA, Fidler WJ, Pinals RS. The epidemiology of giant cell arteritis: report of a ten-year study in Shelby County, Tennessee. Arthritis Rheum 1983; 26:1214–1219
   Google Scholar
• Kobayashi S, Yano T, Matsumoto Y, et al. Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: the first government-supported nationwide survey. Arthritis Rheum. 2003;49:594–598.
   PubMed Web of Science ®Google Scholar
• Franzen P, Sutinen S, von Knorring J. Giant cell arteritis and polymyalgia rheumatica in a region of Finland: an epidemiologic, clinical and pathologic study, 1984-1988. J Rheumatol. 1992;19:273–276.
   PubMed Web of Science ®Google Scholar
• Kemp A. Monozygotic twins with temporal arteritis and ophthalmic arteritis. Acta Ophthalmol (Copenh). 1977;55:183–190.
   PubMed Web of Science ®Google Scholar
• Wernick R, Davey M, Bonafede P. Familial giant cell arteritis: report of an HLA-typed sibling pair and a review of the literature. Clin Exp Rheumatol 1994; 12:63–66
   PubMed Web of Science ®Google Scholar
• Liozon E, Outtara B, Rhaiem K, et al. Familial aggregation in giant cell arteritis and polymyalgia rheumatica: a comprehensive literature review including 4 new families. Clin Exp Rheumatol. 2009;27:S89.
   PubMed Web of Science ®Google Scholar
• Evans JM, O’Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. Ann Intern Med. 1995;122:502–507.
   PubMed Web of Science ®Google Scholar
• Gran JT, Myklebust G, Wilsgaaard T, et al. Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls. Rheumatology (Oxford). 2001;40:1238.
   PubMed Web of Science ®Google Scholar
• Hill CL, Black RJ, Nossent JC, et al. Risk of mortality in patients with giant cell arteritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2017;46:513.
   PubMed Web of Science ®Google Scholar
• Weyland C, Goronzy J. Immune Mechanisms in Medium and Large Vessel Vasculitis. Nat Rev Rheumatol. 2013;12:730–740.
   Google Scholar
• Mackie S, Hensor E, Morgan, A, et al. Should I send my patient with previous giant cell arteritis for imaging of the thoracic aorta? A systemic literature review and meta-analysis. Ann Rheum Dis. 2012;73:143–8.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica and giant-cell arteritis (review). N Engl J Med. 2002;347:261–271.
   PubMed Web of Science ®Google Scholar
• Dejaco C, Brouwer E, Mason JC, et al. Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. Nat Rev Rheumatol. 2017;13:578.
   PubMed Web of Science ®Google Scholar
• Ciccia F, Rizzo A, Ferrante A, et al. New insights into the pathogenesis of giant cell arteritis. Autoimmun Rev. 2017;16:675.
   PubMed Web of Science ®Google Scholar
• Weyand C, Hunder N, Hicok, K, et al. HLA-DRB1 in polymyalgia rheumatica, giant cell arteritis, and rheumatoid arthritis. Arthritis Rheumatism. 1994;37:514–520.
   PubMed Web of Science ®Google Scholar
• Carmona D, Mackie S, Jose-Ezequiel M, et al. A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. Am J Hum Genet. 2015;96:569.
   Web of Science ®Google Scholar
• Carmona D, Vaglio A, Mackie, S, et al. A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. Am J Hum Genet. 2017;100:64.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Gabriel S E, OFallon, W, et al. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med. 1995;123:192–194.
   PubMed Web of Science ®Google Scholar
• Cherry J. Parvoviruses. In: Feigin R, Cherry J, editors. Textbook of pediatric infectious diseases. Philadelphia: WB Saunders; 1992.Vol. 3 p. 1626–1633.
   Google Scholar
• Elling P, Olsson AT, Elling H. Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection. J Rheumatol. 1996;23:112–119.
   PubMed Web of Science ®Google Scholar
• Gabriel SE, Espy M, Erdman DD, et al. The role of parvovirus B19 in the pathogenesis of giant cell arteritis: a preliminary evaluation. Arthritis Rheum. 1999;42:1255–1258.
   PubMed Web of Science ®Google Scholar
• Bhatt A, Manzo V, Pedamallu, C, et al. In search of a candidate pathogen for giant cell arteritis: sequencing-based characterization of the giant cell arteritis microbiome. Arthritis Rheumatol. 2014;66:1939–1944.
   PubMed Web of Science ®Google Scholar
• Sammel A, Smith S, Nguyen, K, et al. Assessment for varicella zoster virus in patients newly suspected of having giant cell arteritis. Rheumatology (Oxford). 2020;59:1992–1996.
   PubMed Web of Science ®Google Scholar
• Getz T, Hoffman G, Padmanabhan, R, et al. Microbiomes of Inflammatory Thoracic Aortic Aneurysms Due to Giant Cell Arteritis and Clinically Isolated Aortitis Differ From Those of Non-Inflammatory Aneurysms. Pathog Immun. 2019;4:105.
   PubMedGoogle Scholar
• Belizna CC, Hamidou MA, Levesque, H, et al. Infection and vasculitis. Rheumatology (Oxford). 2009;48(5):475–482.
   PubMed Web of Science ®Google Scholar
• Duhaut P, Bosshard S, Calvet A. Giant cell arteritis, polymyalgia rheumatica, and viral hypotheses: a multicenter, prospective case-control study. J of Rheumatol. 1000;26:361–369.
   PubMed Web of Science ®Google Scholar
• Ma-Krua W, Jeon MS, Spoerl, S, et al. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med. 2004;199:173.
   PubMed Web of Science ®Google Scholar
• Weyand C, Wei M-K, Pryshchep O, et al. Vascular dendritic cells in giant cell arteritis. Ann N Y Acad Sci. 2005;1062:195–208.
   PubMed Web of Science ®Google Scholar
• Zhang H, Watanabe R, Gerry G, et al. Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. Proc Natl Acad Sci USA. 2017;114:E970–E979.
   PubMed Web of Science ®Google Scholar
• Baik A, Tsai K, Oh D, et al. Mechanisms and Clinical Manifestations of Cardiovascular Toxicities Associated with Immune Checkpoint Inhibitors. Clin Sci (Lond). 2022;135:703–724.
   Web of Science ®Google Scholar
• Micaily I, Chernoff M. An unknown reaction to pembrolizumab: giant cell arteritis. Ann Oncol. 2017;28:2621.
   PubMed Web of Science ®Google Scholar
• Weyand C, Younge BR, Goronzy J, et al. IFN-gamma and IL-17: the two faces of T cell pathology in giant cell arteritis. Curr Opin Rheumatol. 2011;23:43–49.
   PubMed Web of Science ®Google Scholar
• Weyand C, Goronzy J. Giant Cell Arteritis and Polymyalgia Rheumatica. N Engl J Med. 2014;371:50–57.
   PubMed Web of Science ®Google Scholar
• Espigol-Frigole G, Planas-Rigol E, Ohnuki H, et al. Identification of IL-23p19 as an endothelial proinflammatory peptide that promotes gp130-State3 signaling. Sci Signal. 2016;9:28.
   Web of Science ®Google Scholar
• Zerbini A, Muratore F, Boiardi L, et al. Increased expression of interleukin-22 in patients with giant cell arteritis. Rheumatology (Oxford). 2018;57:64.
   PubMed Web of Science ®Google Scholar
• Epigal-Frigole G, Corbera-Bellalta M, Planas-Rigol E, et al. Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis. Ann Rheum Dis. 2013;72:1481.
   PubMed Web of Science ®Google Scholar
• Weyand C, Hicok K, Hunder G, et al. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med. 1994;121:484.
   PubMed Web of Science ®Google Scholar
• Wagner A, Goronzy J, Weyand C, et al. Functional profile of tissue infiltrating and circulating CD68+ cells in giant cell arteritis. Evidence for two components of the disease. J Clin Invest. 1994;94:1134–1140.
   PubMed Web of Science ®Google Scholar
• Hernandez-Rodriguez J, Segarra M, Vilardell C, et al. Tissue production of pro-inflammatory cytokines (IL-1 beta, TNF alpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant cell arteritis. Rheumatology (Oxford). 2004;43:294.
   PubMed Web of Science ®Google Scholar
• Wen Z, Shen Y, Berry G, et al. The microvascular niche instructs T cells in large vessel vasculitis via the VEGF-Jagged1-Notch pathway. Sci Transl Med. 2017;9:399.
   Web of Science ®Google Scholar
• Cid M, Cebrian M, Font C, et al. Cell adhesion molecules in the development of inflammatory infiltrates in giant cell arteritis: inflammation-induced angiogenesis as the preferential site of leukocyte-endothelial cell interactions. Arthritis Rheum. 2000;43:184.
   PubMed Web of Science ®Google Scholar
• Segarra M, Garcia-Martinez A, Sancez M, et al. Gelatinase expression and proteolytic activity in giant cell arteritis. Ann Rheum Dis. 2007;66:1429–1435.
   PubMed Web of Science ®Google Scholar
• Parreau S, Vedrenne N, Regent A, et al. An immunohistochemical analysis of fibroblasts in giant cell arteritis. In: Ann of Diag Path. 2021. p. 52.
   Google Scholar
• Lozano E, Segarra M, Corbera-Bellalta M, et al. Increased expression of the endothelin system in arterial lesions from patients with giant-cell arteritis: association between elevated plasma endothelin levels and the development of ischaemic events. Ann Rheum Dis. 2010;69:434.
   PubMed Web of Science ®Google Scholar
• Regent A, Ly K, Groh M, et al. Molecular analysis of vascular smooth muscle cells from patients with giant cell arteritis: targeting endothelin-1 receptor to control proliferation. Autoimmun Rev. 2017;16:398.
   PubMed Web of Science ®Google Scholar
• Calamia K, Hunder G. Giant Cell Arteritis (Temporal Arteritis) Presenting as Fever of Undetermined Origin. Arthritis Rheum. 1981;24:1414.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay M, Barros S, Lopez-Diaz M, et al. Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine (Baltimore). 2005;84:269.
   PubMed Web of Science ®Google Scholar
• Solomon S, Cappa K. The Headache of Temporal Arteritis. Journ of Am Ger Soc. 1987;35:163–165.
   PubMed Web of Science ®Google Scholar
• Peral-Cagigal B, Perez-Villar A, Luis-Miguel R, et al. Temporal headache and jaw claudication may be the key for the diagnosis of giant cell arteritis. Med Oral Patol Oral Cir Bucal. 2018;23:e290–e294.
   PubMed Web of Science ®Google Scholar
• Gabriel S, O’Fallon W, Achkar A, et al. The use of clinical characteristics to predict the results of temporal artery biopsy among patients with suspected giant cell arteritis. J Rheumatol. 1995;22:93.
   PubMed Web of Science ®Google Scholar
• Smetana GW, Shmerling RH. Does this patient have temporal arteritis? JAMA. 2002;287:92–101.
   PubMed Web of Science ®Google Scholar
• Hunder G. Clinical features of GCA/PMR. Clin & Exp Rheum. 2000;18:S6–S8.
   PubMed Web of Science ®Google Scholar
• Cough and giant cell arteritis. Clinical picture. Qjm. 2018;111:747–748.
   PubMed Web of Science ®Google Scholar
• Soriano A, Muratore F, Pipitone N, et al. Visual loss and other cranial ischaemic complications in giant cell arteritis. Nat Rev Rheumatol. 2017;13:476–484.
   PubMed Web of Science ®Google Scholar
• Hayreh S, Podhajsky P, Zimmerman B. Ocular manifestations of giant cell arteritis. Am J. Opthalmol. 1998;4:509–520.
   Web of Science ®Google Scholar
• Vodopivec I, Rizzo J. Opthalmic manifestations of giant cell arteritis. Rheumatology. 2018;57:ii63–ii72.
   PubMed Web of Science ®Google Scholar
• Seo P, Stone J. Large vessel vasculitis. Arthrit & Rheum. 2004;51:128–139.
   PubMed Web of Science ®Google Scholar
• Nesher G, Nesher R, Rozenman Y, et al. Visual hallucinations in giant cell arteritis: association with visual loss. J Rheumatol. 2001;28:2046–2048.
   PubMed Web of Science ®Google Scholar
• Vukicevic M, Fitzmaurice K. Butterflies and black lacy patterns: the prevalence and characteristics of Charles Bonnet hallucinations in an Australian population. Clin Experiment Ophthalmol. 2008;36:659–665.
   PubMed Web of Science ®Google Scholar
• Mariam I. Donaldson L Jeeva-Patel T. In: Ischemic ocular manifestations of giant cell arteritis: a Canadian case series. Jour of Neur Science. 2022. p. 436.
   Google Scholar
• Liozon E, Dalmay F, Lalloue F, et al. Risk Factors for Permanent Visual Loss in Biopsy-proven Giant Cell Arteritis: a Study of 339 Patients. Journ of Rheumat. 2016;43:1393–1399.
   PubMed Web of Science ®Google Scholar
• Foroozan R, Deramo V, Buono L, et al. Recovery of visual function in patients with biopsy proven giant cell arteritis. Opthalmology. 2003;110(3):539–542.
   PubMed Web of Science ®Google Scholar
• Chacko JG, Chacko JA, Salter MW. Review of Giant cell arteritis. Saudi J Ophthalmol. 2015;29:48–52.
   PubMed Web of Science ®Google Scholar
• Hayreh S, Podhajsky P, Zimmerman B. Occult giant cell arteritis: ocular manifestations. Am J Ophthalmol. 1998;4:521–526.
   Web of Science ®Google Scholar
• Chen J, Leavitt J, Changbo F, et al. Evaluate the Incidence of Arteritic Ischemic Optic Neuropathy and Other Causes of Vision Loss from Giant Cell Arteritis. Ophthalmology.
   Google Scholar
• Hayreh S. Posterior ischaemic optic neuropathy: clinical features, pathogenesis, and management. Eye. 2004;18:1188–1206.
   PubMed Web of Science ®Google Scholar
• Schadlu A, Schadlu R, Banks S. Charles Bonnet syndrome: a review.Curr. Opin in Ophth. 2009;20:219–222.
   PubMed Web of Science ®Google Scholar
• De Smith E, O’Sullivan E, Mackey E, et al. Giant cell arteritis: ophthalmic manifestations of a systemic disease. Clin Exp Ophthalmol. 2016;12:2291–2306.
   Google Scholar
• Cavallini G, Volante V, Bigliard M, et al. Bilateral posterior scleritis as a presenting manifestation of giant cell arteritis: a case report. Can J Ophthalmol. 2014;49:141–143.
   PubMed Web of Science ®Google Scholar
• Papathanassiou M, Elezoglu A, Nikita E, et al. A rare case of peripheral ulcerative keratitis in temporal arteritis. Eur J Ophthalmol. 2009;19:866–869.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay M, Barros S, Lopez-Diaz M, et al. Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine (Baltimore). 2005;84:269–276.
   PubMed Web of Science ®Google Scholar
• Ostberg G. An arteritis with special reference to polymyalgia arteritica. Acta Pathol Microbiol Scand Suppl. 1973;237:1–59.
   Google Scholar
• Miller D, Isotalo P, Weyand C, et al. Surgical pathology of non-infectious ascending aortitis: a study of 45 cases with emphasis on an isolated variant. Am J Surg Pathol. 2006;30:1150–1158.
   PubMed Web of Science ®Google Scholar
• Prieto-Gonzalez S, Arguis P, Garcia-Martinez A, et al. Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography. Ann Rheum Dis. 2012;71:1170–1176.
   PubMed Web of Science ®Google Scholar
• Ghinoi A, Pipitone N, Nicolini A, et al. Large-vessel involvement in recent-onset giant cell arteritis: a case-control colour-Doppler sonography study. Rheumatology (Oxford). 2012;51:730–734.
   PubMed Web of Science ®Google Scholar
• Blockmans D, DeCeuninck L, Vanderschueren S, et al. Repetitive 18F-flurodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum. 2006;55:131–137.
   PubMed Web of Science ®Google Scholar
• Muratore F, Kermani T, Crowson C, et al. Large-vessel giant cell arteritis: a cohort study. Rheumatology (Oxford). 2015;54:463–470.
   PubMed Web of Science ®Google Scholar
• Evans JM, O’Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis: a population-based study. Ann Intern Med. 1995;122:502–507.
   PubMed Web of Science ®Google Scholar
• Nuenninghoff D, Hunder G, Christianson T, et al. Incidence and predictors of large artery complication (aortic aneurysm, aortic dissection, and/or large artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum. 2003;48:3522.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay M, Garcia-Porrua C, Piñeiro A, et al. Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study. Medicine (Baltimore). 2004;83:335–341.
   PubMed Web of Science ®Google Scholar
• Marie I, Proux A, Duhaut P, et al. Long-term follow-up of aortic involvement in giant cell arteritis: a series of 48 patients. Medicine (Baltimore). 2009;88:182–192.
   PubMed Web of Science ®Google Scholar
• Nuenninghoff DM, Hunder GG, Christianson TJ, et al. Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum. 2003;48:3532.
   PubMed Web of Science ®Google Scholar
• Garcia-Martinez A, Hernandez-Rodriguez J, Arguis P, et al. Development of Aortic Aneurysm/Dilatation During the Follow up of Patients with Giant Cell Arteritis: a Cross-Sectional Screening of Fifty-Four Prospectively Followed Patients. Arth & Rheum. 2008;59:422–430.
   PubMed Web of Science ®Google Scholar
• Garcia-Martinez A, Arguis P, Prieto-Gonzalez S, et al. Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilation). Ann Rheum Dis. 2014;73:1826–1832.
   PubMed Web of Science ®Google Scholar
• Kebed D, Bois J, Connolly H, et al. Spectrum of Aortic Disease in the Giant Cell Arteritis Population. Amer Jour of Cardio. 2018;121:501–508.
   PubMed Web of Science ®Google Scholar
• Boysson H, Espitia O, Samson M, et al. Giant cell arteritis-related aortic dissection: a multicenter retrospective study. Sem in Arthr % Rheum. 2021;51:43–435.
   PubMed Web of Science ®Google Scholar
• Tanaz K, Warrington K, Crowson C, et al. Predictors of Dissection in Aortic Aneurysms from Giant Cell Arteritis. J Clin Rheum. 1994;22:184–187.
   Google Scholar
• Mackie S, Hensor E, Morgan A, et al. Should I send my patient with previous giant cell arteritis for imaging of the thoracic aorta? A systemic literature review and meta-analysis. Ann Rheum Dis. 2014;74:143–8.
   Web of Science ®Google Scholar
• Gonzalez-Gay M, Vazquez-Rodriguez T, Gomez-Acebo I, et al. Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine (Baltimore). 2009;88:227–235.
   PubMed Web of Science ®Google Scholar
• Caselli R, Huner G, Whisnant J. Neurologic disease in biopsy-proven giant cell (temporal) arteritis. Neurology. 1988;38:352–359.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay M, Blanco R, Rodriguez V, et al. Permanent vision loss and cerebrovascular accidednts in giant cell arteritis. In: Predictors and response to treatment. Arthritis Rheum. 1998. p. 1497–1504.
   Google Scholar
• Nesher G. Neurologic manifestations of giant cell arteritis. Clin Exp Rheumatol. 2000;18:S24–6.
   PubMed Web of Science ®Google Scholar
• Arnold AC. Ischemic optic neuropathy. In: Miller NR, Newman NJ, Biousse V, editors. Clinical Neuro-Ophthalmology. 6th ed. Philadelphia: Williams & Wilkins; 2005; 1. p. 349–384.
   Google Scholar
• Laneau K, Newman N, Biousse V. Ischemic Optic Neuropathies. Neurologist. 2008;14:341–354.
   PubMed Web of Science ®Google Scholar
• De Smith E, O’Sullivan E, Mackey D, et al. Giant cell arteritis: ophthalmic manifestations of a systemic disease. Arch Clin Exp Ophthalmol. 2016;254:2291–2306.
   Web of Science ®Google Scholar
• Gonzalez-Gay M, Lopez-Diaz M, Barros S, et al. Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients. Medicine (Baltimore). 2005;84:277–290.
   PubMed Web of Science ®Google Scholar
• Schmidt W, Kraft H, Volker L, et al. Colour Doppler sonography to diagnose temporal arteritis. Lancet. 1995;345:866.
   PubMed Web of Science ®Google Scholar
• Van der Geest K, Wolfe K, Borg F, et al. Ultrasonographic Halo Score in giant cell arteritis: association with intimal hyperplasia and ischaemic sight loss. Rheumatology (Oxford). 2020;60:4361–4366.
   Web of Science ®Google Scholar
• Sebastian A, Coath F, Innes S, et al. Role of the halo sign in the assessment of giant cell arteritis: a systemic review and meta-analysis. Rheum Adv in Pract. 2021:3:5.
   Google Scholar
• Arida A, Kyprianou M, Kanakis M, et al. The diagnostic value of ultrasonography-derived edema of the temporal artery wall in giant cell arteritis: a second meta-analysis. BMC Musc Dis. 2010;11:44.
   PubMed Web of Science ®Google Scholar
• Ball E, Walsh S, Tang T, et al. Role of ultrasonography in the diagnosis of temporal arteritis. Br J Surg. 2010;97:1765–1771.
   PubMed Web of Science ®Google Scholar
• Duftner C, Dejaco C, Sepriano A, et al. Imaging in diagnosis, outcome prediction and monitoring of large vessel vasculitis: a systemic literature review and meta-analysis informing the EULAR recommendations. eCollection: RMD Open; 2018.
   Google Scholar
• Rinagel M, Chatelus E, Jousse-Joulin S, et al. Diagnostic performance of temporal artery ultrasound for the diagnosis of giant cell arteritis: a systemic review and meta-analysis of the literature. Autoimmun Rev. 2019;18:56–61.
   PubMed Web of Science ®Google Scholar
• Imfeld A, Staub D, Baldi T, et al. The ultrasound compression sign to diagnose temporal giant cell arteritis shows an excellent interobserver agreement. Clin Exp Rheumatol. 2015;33(2 Suppl):89).
   PubMed Web of Science ®Google Scholar
• Diamantopoulos A, Haugerberg G, Hetland H, et al. Diagnostic value of color Doppler ultrasonography of temporal arteries and large vessels in giant cell arteritis: a consecutive case series. Arthritis Care Res. 2014;66:113–119.
   PubMed Web of Science ®Google Scholar
• Loffler C, Hoffend J, Benck U, et al. The value of ultrasound in diagnosing extracranial large-vessel vasculitis compared to FDG-PET/CT: a retrospective study. Clin Rheumatol. 2017;36:2079–2086.
   PubMed Web of Science ®Google Scholar
• Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis. 2018;7:636–643.
   Web of Science ®Google Scholar
• Berthod P, Aho-Glele S, Ornetti P, et al. CT analysis of the aorta in giant-cell arteritis: a case-control study. Eur Radiol. 2018;28:3676–3684.
   PubMed Web of Science ®Google Scholar
• Lariviere D, Benali K, Coustet B, et al. Positron emission tomography and computed tomography angiography for the diagnosis of giant cell arteritis. A real-life prospective study. Medicine (Baltimore). 2016;95:e4146.
   PubMed Web of Science ®Google Scholar
• Geiger J, Bley T, Uhl M, et al. Diagnostic value of T2-weighted imaging for the detection of superficial cranial artery inflammation in giant cell arteritis. J Magn Reson Imaging. 2010;31:470–474.
   PubMed Web of Science ®Google Scholar
• Berger C, Sommer G, Aschwanden M, et al. The clinical benefit of imaging in the diagnosis and treatment of giant cell arteritis. Swiss Med Wkly. 2018;148:w14661.
   PubMed Web of Science ®Google Scholar
• Stellingwerff M, Brouwer E, Lensen K, et al. Different scoring methods of FDG PET/CT in Giant Cell Arteritis: need for Standardization. Medicine (Baltimore). 2015;94:e1542.
   PubMed Web of Science ®Google Scholar
• Puppo C, Massollo M, Paporo F, et al. Giant cell arteritis: a systemic review of the qualitative and semiquantitative methods to assess vasculitis with 18f fluorodeoxyglucose positron emission tomography. Biol Med Res Int. 2014;2014:574248.
   PubMed Web of Science ®Google Scholar
• Blockmans D, Stroobants S, Maes A, et al. Positron emission tomography in giant cell arteritis and polymyalgia rheumatica evidence for inflammation of the aortic arch. Am J Med. 2000;108:246–249.
   PubMed Web of Science ®Google Scholar
• Hommada M, Mekinian A, Brillet PY, et al. Aortitis in giant cell arteritis: diagnosis with FDG PET/CT and agreement with CT angiography. Autoimmun Rev. 2017;16:1131–1137.
   PubMed Web of Science ®Google Scholar
• Pfadenhauer K, Weinerth J, Hrdina C. Vertebral arteries: a target for FDG-PET imaging in giant cell arteritis? Clinical, ultrasonographic and PET study in 46 patients. Nucl Med (Stuttg). 2011;50:28–32.
   Web of Science ®Google Scholar
• Quinn KA, Ahlman MA, Malayeri AA, et al. Comparison of magnetic resonance angiography and 18Ffluorodeoxyglucose positron emission tomography in large-vessel vasculitis. Ann Rheum Dis. 2018;77:1165–1171.
   PubMed Web of Science ®Google Scholar
• Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79:19–30.
   PubMed Web of Science ®Google Scholar
• Maz M, Chung S, Abril A, et al. American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. In: Arthritis Care & Research.2021;73:1349–1365.
   Google Scholar
• Grayson P, Alehashemi S, Bagheri A, et al. Positron Emission Tomography as an Imaging Biomarker in a Prospective, Longitudinal Cohort of Patients with Large Vessel Vasculitis. Arthritis Rheumatol. 208;70:439–449.
   PubMed Web of Science ®Google Scholar
• Reichenbach S, Adler S, Bonel H, et al. Magnetic resonance angiography in giant cell arteritis: results of a randomized controlled trial of tocilizumab in giant cell arteritis. Rheumatology. 2018;57:982–986.
   PubMed Web of Science ®Google Scholar
• Danesh-Meyer H, Savino P, Bilyk J, et al. Shrinkage: fact or fiction? Arch Ophthalmol. 2001;119:1217.
   PubMedGoogle Scholar
• Rubenstein E, Maldini C, Gonzalez-Chiappe S, et al. Sensitivity of temporal artery biopsy in the diagnosis of giant cell arteritis: a systematic literature review and meta-analysis. Rheumatology (Oxford). 2020;59:1011.
   PubMed Web of Science ®Google Scholar
• Genereau T, Lortholary O, Pottier MA, et al. Temporal artery biopsy: a diagnostic tool for systemic necrotizing vasculitis. French Vasculitis Study Group. Arthritis Rheum 1999;42:2674–2681.
   PubMed Web of Science ®Google Scholar
• Robinette M, Rao D, Monach P. The Immunopathology of Giant Cell Arteritis across disease spectra. Front Immunol. 2021;12.
   PubMed Web of Science ®Google Scholar
• Weyand CM, Ma-Krupa W, Goronzy J. Immunopathways in giant cell arteritis and polymyalgia rheumatica. Autoimmun Rev. 2004;3:46–53.
   PubMed Web of Science ®Google Scholar
• Aiello P, Trautmann J, McPhee T, et al. Visual Prognosis in Giant Cell Arteritis. Ophthalmol. 1993;11:550–555.
   Google Scholar
• Chan CC, Paine M, O’Day J. Steroid management in giant cell arteritis. Br J Ophthalmol. 2001;85:1061–1064.
   PubMed Web of Science ®Google Scholar
• Hayreh SS, Zimmerman B, Kardon RH. Visual improvement with corticosteroid therapy in giant cell arteritis: report of a large study and review of literature. Acta Ophthalmol Scand 2002;80:355–367.
   PubMedGoogle Scholar
• Rucker J, Biousse V, Newman N. Ischemic optic neuropathies. Current Opin Neuro. 2004;17:27–35.
   PubMed Web of Science ®Google Scholar
• Kermani T, Warrington K, Cuthberston D. Disease relapses among patients with giant cell arteritis: a prospective, longitudinal cohort study. J Rheumatol. 2015;42:1213–1217.
   PubMed Web of Science ®Google Scholar
• Alba M, Garcia-Martinez P-GS, Prieto-González, S, et al. Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Medicine (Baltimore). 2014;93:194.
   PubMed Web of Science ®Google Scholar
• Restuccia G, Cavazza A, Catanoso M, et al. Flares in Biopsy-Proven Giant Cell Arteritis in Northern Italy: Characteristics and Predictors in a Long-Term Follow-Up Study. Medicine (Baltimore) 2016;Vol. 95:e3524.
   PubMed Web of Science ®Google Scholar
• Unizony S, Arias-Udaneta L, Miloslavsky E, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res. 2012;64:1720–1729.
   PubMed Web of Science ®Google Scholar
• Stone J, Tuckwell K, Dimonaco S, et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017;377:317–328.
   PubMed Web of Science ®Google Scholar
• Adler S, Reichenbach S, Gloor A, et al. Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis. Rheumatology. 2019;58:1639–1643.
   PubMed Web of Science ®Google Scholar
• Hoffman G, Hellman D, Huillevin L, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002;46:1309.
   PubMed Web of Science ®Google Scholar
• Jover J, Hernandez-Garcia C, Morado I, et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134:106.
   PubMed Web of Science ®Google Scholar
• Spiera R, Mitnick H, Kupersmith M, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol. 2001;19:495–501.
   PubMed Web of Science ®Google Scholar
• Mahr A, Jover J, Spiera R, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007;8:2789–2797.
   Web of Science ®Google Scholar
• Langord C, Cuthberston S, Ytterberg, et al. A randomized, double-blind trial of Abatacept (CTLA-4Ig) for the treatment of Giant cell arteritis. Arthritis Rheumatol. 2017;69 Epub:837–845.
   Web of Science ®Google Scholar
• De Silva M, Hazleman B. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis. 1986;45:136.
   PubMed Web of Science ®Google Scholar
• Conway R, O’Neill L, O’Flnn E, et al. Ustekinumab for the treatment of refractory giant cell arteritis. Ann Rheum Dis. 2016;75:1578.
   PubMed Web of Science ®Google Scholar
• Ly K, Dalmay F, Gondran G, et al. Steroid-sparing effect and toxicity of dapsone treatment in giant cell arteritis: a single-center, retrospective study of 70 patients. Medicine (Baltimore). 2016;95:e4974.
   PubMed Web of Science ®Google Scholar
• Diamantopoulos A, Hetland H, Myklebust G. Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatic: a case series. Biomed Res Int. 2013;2013;120638.
   PubMed Web of Science ®Google Scholar
• Deshayes S, Ly K, Rieu V, et al. POS0338 Steroid-sparing effect of anakinra in giant-cell arteritis: a case series with clinical, biological and iconographic long-term assessments. Scientific Abstracts: Poster Tours vasculitis-large vessel vasculitis.
   Google Scholar